clinical trial · NCT03673501
A Study of Ripretinib vs Sunitinib in Advanced GIST Patients After Treatment With Imatinib
Deciphera Pharmaceuticals, LLC·phase3·active not recruiting·n = 453
Gastrointestinal Stromal TumorsRipretinibSunitinib
brief summary
This is a 2-arm, randomized, open-label, international, multicenter study comparing the efficacy of ripretinib to sunitinib in GIST patients who progressed on or were intolerant to first-line anticancer treatment with imatinib. Approximately 426 patients will be randomized in a 1:1 ratio to ripretinib 150 mg once daily (continuous dosing for 6 week cycles) or sunitinib 50 mg once daily (6 week cycles, 4 weeks on, 2 weeks off).
started
Feb 8, 2019
primary completion
Sep 1, 2021
completion
Dec 1, 2026
last updated
Feb 5, 2026
official title
A Phase 3, Interventional, Randomized, Multicenter, Open-Label Study of Ripretinib vs Sunitinib in Patients With Advanced Gastrointestinal Stromal Tumor (GIST) After Treatment With Imatinib
sourced from ClinicalTrials.gov · pharmadog mirrors structured fields, not the full protocol